REGENERON PHARMACEUTICALS

Regeneron’s 4,147‑share Form 144 filing shows a routine executive option sale, revealing internal confidence yet minimal market impact for the biotech firm.

Regeneron & Hansoh Pharma launch Olatorepatide, a dual‑biased GLP‑1/GIP drug poised to hit the $25 B obesity market and $55 B T2D segment with 8 % weight loss and low GI risk, offering strong ROI and M&A upside.

Regeneron and Sanofi’s $8 billion alliance launches long‑acting antibodies for type‑2 inflammation, aiming to boost adherence and capture a larger immune‑disease market.

Discover Novo Nordisk’s worldwide license for HRS‑1596, a weekly oral dual‑agonist obesity pill targeting GLP‑1 and GIP receptors, promising improved adherence and weight‑loss efficacy.

Regeneron’s pozelimab‑cemdisiran combo targets C5 production and activity, offering stronger hemolysis control for PNH patients who fall short on current anti‑C5 drugs.